Chrysalis BioTherapeutics is a biopharmaceutical company that develops regenerative drugs for respiratory disorders and acute radiation exposure. It offers TP508, an injectable drug used to mitigate vascular damage, hemorrhage, and inflammation observed in acute respiratory distress syndrome (ARDS) induced by viral infection (COVID-19) and nuclear radiation.